Entering text into the input field will update the search result below

Lilly's Cyramza flunks Phase 3 trial in liver cancer; new one planned

Jun. 19, 2015 9:02 AM ETEli Lilly and Company (LLY) StockAMGN, LLY, BAYRYBy: Douglas W. House, SA News Editor
  • A Phase 3 study, called REACH, evaluating Eli Lilly's (NYSE:LLY) Cyramza (ramucirumab) as second-line treatment [after Nexavar (sorafenib)] in patients with hepatocellular carcinoma (HCC) failed to achieve its primary endpoint of a statistically significant improvement in overall survival (OS). Median OS in the Cyramza plus best supportive care (BSC) arm was 9.2 months versus 7.6 months in the placebo plus BSC arm (p=0.1391). The results were published in The Lancet Oncology.
  • A prespecified subgroup of HCC patients with elevated baseline alpha-fetoprotein (AFP), a liver enzyme, did show a statistically valid improvement in survival after receiving ramucirumab. Median OS was 7.8 months compared to 4.2 months for placebo (p=0.0059).
  • The company plans to conduct an new Phase 3 study, called REACH-2, to assess Cyramza in a second-line setting in patients with elevated AFP. Enrollment will begin shortly.
  • Cyramza is currently approved for the treatment of certain colorectal, gastric and lung cancers and gastroesophageal junction adenocarcinoma.
  • Related tickers: (NASDAQ:AMGN) (OTCPK:BAYRY)

Recommended For You

More Trending News

About LLY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LLY--
Eli Lilly and Company
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.